M. Praus

发表

Effects of low-molecular weight and high-molecular weight heparin on the intrinsic and extrinsic endogenous fibrinolytic system

J. Schulz-Menger, R. Dietz, R. Dechend, 1994 .

Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy

H. Hartung, G. Sobue, R. Lewis, 2021, CPT: pharmacometrics & systems pharmacology.

Reduction of tumor cell migration and metastasis by adenoviral gene transfer of plasminogen activator inhibitors

R. Gerard, D. Collen, M. Praus, 1999, Gene Therapy.

The Plasma Supplemented Modified Activated Clotting Time for Monitoring of Heparinization During Cardiopulmonary Bypass: A Pilot Investigation

A. Koster, G. Despotis, J. Levy, 2002, Anesthesia and analgesia.

Heparin-Level-Based Anticoagulation Management During Cardiopulmonary Bypass: A Pilot Investigation on the Effects of a Half-Dose Aprotinin Protocol on Postoperative Blood Loss and Hemostatic Activation and Inflammatory Response

W. Kuebler, A. Koster, F. Merkle, 2004, Anesthesia and analgesia.

The Plasminogen Activator Inhibitor PAI-1 Controls in Vivo Tumor Vascularization by Interaction with Proteases, Not Vitronectin

P. Carmeliet, J. Foidart, A. Noël, 2001, The Journal of cell biology.

DSPA alpha — Properties of the plasminogen activators of the vampire bat Desmodus rotundus

D. Gulba, M. Praus, W. Witt, 1995 .

Both u‐PA inhibition and vitronectin binding by plasminogen activator inhibitor 1 regulate HT1080 fibrosarcoma cell metastasis

R. Gerard, D. Collen, M. Praus, 2002, International journal of cancer.

Phase I Comparability of Recombinant Human Albumin and Human Serum Albumin

C. Andresen, J. Waters, L. Nyman, 2005, Journal of clinical pharmacology.

Update on the toxicology and pharmacology of rDSPA alpha 1 (Bat-PA) in animals and humans

R. Dechend, M. Mahler, D. Gulba, 1997 .

Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP

H. Hartung, G. Sobue, R. Lewis, 2019, Neurology: Neuroimmunology & Neuroinflammation.

Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial

G. L. Masson, D. Yarnitsky, S. Muley, 2018, The Lancet Neurology.

Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (CIDP), a multicenter randomized double-blind placebo-controlled trial: the Path study

H. Hartung, G. Sobue, V. Bril, 2017, Journal of the Neurological Sciences.

Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.

W. Keitel, N. Groth, A. Hilbert, 2010, Vaccine.

Prion protein stimulates tissue‐type plasminogen activator‐mediated plasmin generation via a lysine‐binding site on kringle 2

W. Schleuning, M. Praus, R. Geßner, 2004, Journal of thrombosis and haemostasis : JTH.

Stimulation of plasminogen activation by recombinant cellular prion protein is conserved in the NH2-terminal fragment PrP23-110

A. Aguzzi, H. Holzhütter, W. Schleuning, 2003, Thrombosis and Haemostasis.

Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine

M. Zambon, J. Katz, K. Hoschler, 2009, Proceedings of the National Academy of Sciences.

Study design of a prospective, open-label study comparing increased infusion parameters of a 20% subcutaneous immunoglobulin (IgPro20) in patients with primary immunodeficiency

M. Rojavin, M. Praus, Jutta H Hofmann, 2019 .

Hemostatic Activation and Inflammatory Response during Cardiopulmonary Bypass: Impact of Heparin Management

R. Hetzer, W. Kuebler, A. Koster, 2002, Anesthesiology.

Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1.

M. Zambon, J. Katz, K. Hoschler, 2008, The New England journal of medicine.

Two-dimensional maps in the most extended (pH 2.5-11) immobilized pH gradient interval.

P. Righetti, E. Gianazza, E. Köttgen, 1990, Journal of biochemical and biophysical methods.

Systemic IgG exposure and safety in patients with primary immunodeficiency: a randomized crossover study comparing a novel investigational wearable infusor versus the Crono pump.

C. Cunningham-Rundles, N. Patel, R. Wasserman, 2022, Immunotherapy.

The Plasminogen Activator Inhibitor PAI-1 Controls in Vivo Tumor Vascularization by Interaction with Proteases, Not Vitronectin

Nils Brünner, Robert D. Gerard, Geert Carmeliet, 2001, The Journal of cell biology.

Ksp-cadherin is a functional cell-cell adhesion molecule related to LI-cadherin.

M. Hecking, M. Praus, C. Metzig, 2004, Experimental cell research.

Pharmacokinetic Analysis of Weekly Versus Biweekly IgPro20 Dosing in Patients With Primary Immunodeficiency

E. Haddad, M. Tortorici, M. Rojavin, 2019, Clinical pharmacology in drug development.

A randomized phase II study of a new tick-borne encephalitis vaccine using three different doses and two immunization regimens.

U. Klockmann, R. Weber, H. Bock, 1992, Vaccine.

Thrombin receptor and urokinase-type plasminogen activator are colocalized in vascular smooth muscle cells derived from human carotid atherosclerotic plaques

M. Gross, R. Dietz, R. Dechend, 1996 .

The intron 6 G/T polymorphism of c-myb oncogene and the risk for coronary in-stent restenosis

A. Pfeufer, R. Dietz, M. Praus, 2004, Basic Research in Cardiology.

Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations

S. Haertel, A. Banzhoff, M. Praus, 2011, Human vaccines.

Alert systems for post-marketing surveillance of adverse drug reactions.

M. Praus, M Praus, F Schindel, 1993, Statistics in medicine.

Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP

H. Hartung, G. Sobue, R. Lewis, 2019, Neurology: Neuroimmunology & Neuroinflammation.

Safety and Tolerability of Subcutaneous IgPro20 at High Infusion Parameters in Patients with Primary Immunodeficiency: Findings from the Pump-Assisted Administration Cohorts of the HILO Study

N. Patel, D. Vinh, V. Bonagura, 2021, Journal of Clinical Immunology.

Safety and Tolerability of Manual Push Administration of Subcutaneous IgPro20 at High Infusion Rates in Patients with Primary Immunodeficiency: Findings from the Manual Push Administration Cohort of the HILO Study

N. Patel, D. Vinh, V. Bonagura, 2020, Journal of clinical immunology.

Both lysine-clusters of the NH2-terminal prion-protein fragment PrP23-110 are essential for t-PA mediated plasminogen activation

Hermann-Georg Holzhütter, Wolf-Dieter Schleuning, H. Holzhütter, 2004, Thrombosis and Haemostasis.

Humoral immunity against tick-borne encephalitis virus following manifest disease and active immunization.

U. Klockmann, H. Bock, M. Praus, 1991, Vaccine.